Valacyclovir Dose for HSV Prophylaxis
For HSV prophylaxis in adults with normal renal function, valacyclovir 500 mg twice daily is the recommended dose 1, 2.
Dosing by Clinical Context
HIV-Infected Patients
- Standard suppressive dose: 500 mg twice daily 1
- This is specifically recommended for HIV-infected persons with frequent or severe HSV recurrences (AI recommendation)
- Daily suppressive therapy in HIV-infected patients also decreases HIV concentration in plasma and genital secretions 1
- Important caveat: Do NOT use valacyclovir 500 mg twice daily for HSV-2 meningitis prophylaxis—this dose failed to prevent recurrences and may cause rebound 3
Immunocompetent Patients
The FDA-approved dosing for suppressive therapy varies by recurrence frequency 2:
- For ≥10 recurrences/year: 1 gram once daily OR 500 mg twice daily
- For ≤9 recurrences/year: 500 mg once daily (alternate dosing option)
Clinical pearl: While 500 mg once daily may suffice for patients with infrequent recurrences, the twice-daily regimen (500 mg BID) provides more consistent viral suppression and is preferred when preventing transmission is a priority 4.
Renal Dose Adjustments
For patients with renal impairment, adjust as follows 2:
| Creatinine Clearance | Dose Adjustment |
|---|---|
| ≥50 mL/min | No adjustment needed |
| 30-49 mL/min | No adjustment for suppressive therapy |
| 10-29 mL/min | 500 mg every 24 hours |
| <10 mL/min | 500 mg every 24 hours |
| Hemodialysis | 500 mg every 24-48 hours (give after dialysis) |
Special Populations
Pregnancy
- Acyclovir is preferred over valacyclovir due to more extensive safety data 1, 5
- If valacyclovir is used: 500 mg twice daily starting at 36 weeks until delivery 5
Pediatric Patients
- Valacyclovir dosing data in children are limited 6
- For children <45 kg: Use acyclovir 20 mg/kg (max 400 mg) three times daily instead 6
Critical Safety Warnings
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) has occurred with high-dose valacyclovir (8 grams/day) in immunocompromised patients, particularly those with advanced HIV disease 1, 2, 7. This is NOT a concern at standard prophylactic doses (500 mg-1 gram daily), but clinicians should be aware when considering dose escalation.
Evidence Strength
The 500 mg twice daily dosing for HIV-infected patients carries an AI recommendation (strong recommendation, high-quality evidence) from CDC/NIH/IDSA guidelines 1. The dose-response relationship and efficacy of various valacyclovir regimens are well-established through large randomized controlled trials 4.